Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity
Background With the development of targeted agents, the approach to combination cancer therapy has evolved to focus on identifying ways in which pathway inhibition by one agent may enhance the activity of other agents. In theory, this implies that under this new paradigm, agents are no longer requir...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-10-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/5/5/e000871.full |